Oric Pharmaceuticals (ORIC) Goldman Sachs 46th Annual Global Healthcare Conference summary

Company and pipeline overview

• Focused on small molecule therapies for solid tumors, specifically prostate, lung, and breast cancers.

• Two main clinical programs: ORIC-944 (PRC2 inhibitor for prostate cancer) and ORIC-114 (brain-penetrant EGFR/HER2 inhibitor for lung cancer).

• Plans to initiate two phase three studies in 2026, one for each program.

• Multiple clinical readouts expected over the next 12–15 months.

ORIC-944 program highlights

• ORIC-944 addresses limitations of earlier PRC2 inhibitors with improved potency, half-life, and metabolic profile.

• Phase 1b combination data showed a PSA 50 response rate of 47% and PSA 90 of 24%.

• Safety profile appears favorable compared to competitors, with lower rates of severe diarrhea and other adverse events.

• Patient population in trials is more heavily pretreated than comparator studies.

• Dose optimization ongoing, with updates expected in the second half of 2024 and early 2025.

Competitive landscape and strategy

• Pfizer’s Mevrometastat has set a precedent, with ORIC-944 aiming for best-in-class or at least comparable efficacy and safety.

• Differentiation may come from once-daily dosing, improved safety, and higher PSA responses.

• Several other PRC2 inhibitors are in development, but many lack optimization for prostate cancer.

• Strategic partnerships with Bayer and Janssen provide drug supply and feedback, with pivotal development likely to focus on one AR inhibitor partner.